[Tumor markers in focal and diffuse liver diseases]

Area of Science:

• Oncology
• Hepatology
• Clinical Chemistry

Background:

• Tumor markers are used in diagnosing and monitoring various cancers.
• Liver diseases, both benign and malignant, can affect tumor marker levels.
• Understanding these variations is crucial for accurate diagnosis.

Purpose of the Study:

• To evaluate serum tumor marker levels in patients with hepatic and extrahepatic diseases.
• To compare marker concentrations between benign liver diseases, malignant hepatic tumors, and a control group.
• To identify specific tumor markers indicative of hepatic malignancies.

Main Methods:

• Serum levels of alpha-fetoprotein, carcinoembryonic antigen, ferritin, and beta 2-microglobulin were measured.
• 147 patients with benign/malignant hepatic diseases were studied.
• 105 patients with extrahepatic cancer (no liver metastases) and 36 healthy individuals served as controls.

Main Results:

• Increased tumor marker concentrations were observed in patients with malignant and benign hepatic diseases, and in the control group.
• Hepatic tumors exhibited a more frequent and higher elevation of tumor markers compared to benign conditions.
• Hepatitis and cirrhosis showed the most frequent increases in tumor markers among benign liver diseases.

Conclusions:

• While elevated tumor markers are not exclusive to hepatic tumors, their frequency and magnitude can aid in differentiation.
• Specific marker profiles may help distinguish between benign liver conditions, hepatic malignancies, and other cancers.
• Further research into marker combinations could improve diagnostic accuracy for liver diseases.